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Abstract
Apoptosis, known as programmed cell death, has been considered a potent target 
for the pharmacy industry. The scientific community has actively participated to 
research which evaluate active molecules for possible inhibition or induction of 
apoptosis. Nanocarriers especially for cancer targeting are widely found through 
literature; they mainly based on inorganic, lipid or polymer nanoparticles which 
incorporate anticancer drugs. Another important and innovative category of antican-
cer agents is that of microRNAs. In this chapter, a discussion about the most recent 
applications of apoptosis-based agents mainly focusing on cancer target is done.
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1. Introduction
In the last decades, a huge advancement in the development of novel drug targets 
and drug delivery systems for inhibiting or inducing apoptosis has been done. 
Apoptosis, the programmed cell death plays a major role in cellular homeostasis, 
normal development, and clearance of cells. Non-programmed cell death can take 
place by various external factors, such as infection, toxins, and physical injury [1]. 
The dysregulation of apoptosis has been related with the pathogenesis of numerous 
diseases such as degenerative, autoimmune, and cardiovascular as well as have been 
associated with tumorigenesis. It has been reported that apoptosis is reduced on 
pathological disorders such as malignant neoplasm and autoimmune diseases while 
it is raised in inflammatory and neurodegenerative disorders as well as ischemic 
diseases, i.e. myocardial infarction, liver ischemia, stroke [2]. Apoptosis can induce 
cancer formation while cancer cells may elude apoptosis via the downregulation 
or blockage of apoptosis signaling pathways [3]. Similarly, cell death modalities 
(apoptosis, necrosis, and autophagy) have been linked with cardiovascular, autoim-
mune, and neurodegenerative diseases. In example, it has been reported that the 
apoptosis is impaired by various factors (i.e. caspases, amyloid β, tumor necrosis 
factor-α, amyloid precursor protein intracellular C-terminal domain, etc.) leading 
to Alzheimer’s disease and other neurodegenerative diseases (such as Huntington’s 
disease) [4–6]. Moreover, cardiovascular disorders such as myocardial infarction, 
diabetic cardiomyopathy, ischemic cardiomyocyte, and congestive heart failure 
have been associated with cell death modes in cardiac myocytes [7].
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Identification of key players in cellular apoptosis regulation as B-cell lymphoma 
2 (BCL-2) proteins, caspases, etc. has proofed that targeting apoptosis can lead to 
outstanding management of various diseases, especially cancer [8, 9].
2. Nanocarriers inducing apoptosis
In general, pharmacological approaches related to apoptosis can be categorized 
as inhibiting and inducing apoptosis molecules. Inhibitors of apoptosis (IAPs) 
are proteins important for maintaining apoptosis; IAPs have been identified in 
tumors and thus therapies targeting them have raised the research interest. It is well 
known that cancer cells are more resistant to apoptotic cell death, and high dosages 
of drugs are needed to eliminate them [10]. Consequently, the usage of apoptotic 
pathways via IAP antagonism can act as a promising alternative therapeutic choice 
for cancer management, limiting the apoptotic effect on cancerous cells [11]. In case 
of cardiovascular disorders, inhibiting myocardial apoptosis has been recognized 
as a therapeutic target. In the past, caspase inhibitors [12] and control of apoptosis 
of cardiovascular fibroblasts/vascular smooth muscle cells by p65 nuclear fac-
tors NF-κB and B-cell lymphoma-extra-large (Bcl-xL) antisense oligonucleotides 
or p53 overexpression [13] have been reported as potent drug targets. A recent 
study [14] revealed that the upregulation of miR-29b-3p (miRNAs), can protect 
cardiomyocytes against hypoxia-induced injury through downregulation of TNF 
receptor-associated factor 5 which can be an important therapeutic alternative for 
acute myocardial infarction. BH3 interacting-domain death agonist [BID (belongs 
to BCL-2 family)] inhibitors have been recognized as key factors in the apoptotic 
pathway mediating cytochrome C and Smac/DIABLO from mitochondria, resulting 
in caspase activation and cell apoptosis. The inhibition of BID by pharmacologi-
cal agents can offer a promising therapeutic choice for diseases implicated by 
pathological cell death from BID involvement [2]. Becattini et al. developed various 
4-phenylsulfanyl-phenylamine derivatives that are capable of binding on the sur-
face of BID resulting to inhibition of tBid-induced SMAC release, caspase-3 activa-
tion, and cell death [15]. Tumor necrosis factor-like weak inducer of apoptosis 
(TWEAK) inhibitors have been also reported to induce apoptosis; tumor necrosis 
factor (TNF) has been linked with cerebral ischemia, atherosclerosis, rheumatoid 
arthritis, etc. The TWEAK-Fibroblast growth factor-inducible 14 (FN-14) has been 
identified as potent drug target for the aforementioned diseases [16]. Cytochrome C 
inhibitors, as Minocycline and methazolamide have shown inhibition of apoptosis. 
Minocycline revealed inhibition of apoptosis via attenuation of TNF-alpha expres-
sion following iNOS/NO induction by lipopolysaccharide in neuron/glia co-cultures 
[17]. Tian et al. showed that minocycline can inhibit sevoflurane-induced apoptosis 
[18]. Methazolamide, a carbonic anhydrase has shown prevention of the amyloid 
β-mediated onset of apoptosis in the mouse brain [19]. Therefore, various apoptotic 
inhibitors have been developed; however, a great effort is much needed.
A special reference on the drug carriers involved as chemotherapeutic systems 
inducing apoptosis of cancerous cells is followed due to its importance. Cancer is the 
second leading cause of death globally [20] and despite the great effort being done 
by researchers worldwide, its management remains inefficient. Chemotherapy, the 
most conventional treatment option can lead to serious adverse effects since it can 
induce the cell death of healthy tissues as well as the cancerous ones [21]. In most 
cases, the current therapeutic systems involve the use of nanoparticles based on 
polymeric and inorganic carriers and a combination of them. Nanotechnology-based 
carriers are of great interest due to their limited size, improved penetration, and 
functionalization potential resulting to targeting efficiency [22, 23]. The therapeutic 
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outcome of cancer management strategies mainly depends to the ability of the 
molecule to induce apoptosis via targeting the overexpressed anti-apoptotic proteins 
or stimulation of the expression of pro-apoptotic molecules. Nonetheless, cancer 
cells seem to resist the chemotherapy and apoptosis leading to increased survival rate 
and the possibility of metastasis. Thus, the combination of drugs or novel strategies 
involving innovative drug carriers can potentially overcome the chemoresistance 
[24, 25]. Solid lipid nanoparticles belong to lipid-based carriers and have been 
designed as potent drug delivery systems for various diseases. As an example, letro-
zole, a known cytotoxic agent for hormone-dependent breast cancer management 
was impregnated to folic acid-modified solid lipid nanoparticles in order to induce 
apoptotic cell death. The modification with folic acid can lead to enhanced target-
ing efficiency since breast cancer cells overexpressed folate receptors. Inducing of 
apoptosis performed by employing caspase-3 activity and TUNEL assays. The incor-
poration of the drug into the folic acid decorated carriers led to in vitro cytotoxicity 
against MCF-7 cancer cells but they were not cytotoxic to MCF-10A normal cells 
revealing great biocompatibility. It was concluded that the mechanism of cell death 
was apoptosis based [26]. Similarly, solid lipid nanoparticles were modified with 
chitosan-coated-trans-resveratrol and ferulic acid and further decorated with folic 
acid. The developed nano-formulations demonstrated great stability and improved 
cytotoxicity in the colon cancer cells which led to apoptotic cell death. Thus, the 
solid lipid nanoparticles can be used for anticancer therapy [27]. Folate modified 
hydroxyapatite nanorods were used as a matrix for doxorubicin, an anticancer agent, 
loading. The results showed cytotoxicity against MCF-7 cells while western blot 
assays revealed that the developed nanocarriers can improve the expression of Bax 
(a pro-apoptotic protein) and decrease the expression of Bcl-2. Finally, the nanorods 
improved mitochondrial cytochrome C leakage and activate an apoptotic cell death 
[28]. In similar skeptic, folic acid conjugated chitosan nanoparticles were able to 
incorporate the cytotoxic agent, ursolic acid. The targeting affinity improved the 
local concentration of the drug in cancerous cells MCF-7. According to the studies, 
the nanoparticles enter the lysosome, released from it while it was localized into 
mitochondria but not nuclei. Their prolonged retention in mitochondria led to the 
irreversible apoptosis in cancer cells owing to the overproduction of ROS and the 
destruction of the mitochondrial membrane. According to the mouse xenograft 
model, the nanoparticles can hamper breast cancer revealing promising charac-
teristics and potent clinical efficacy [29]. Nano-formulations comprised of amine-
functionalized and conjugated with folic acid mesoporous silica nanoparticles were 
loaded with curcumin, quercetin, and colchicines, known as anticancer prodrugs. 
The folate decorated nanoparticles incorporating curcumin revealed greater cellular 
uptake, prolonged intracellular release, and cytotoxicity. It was also reported that 
the apoptotic cell death was induced through specific signaling molecular pathways 
(caspase-3, H2O2, c-MET, and MCL-1), providing great [30]. In the last years the 
combination of inorganic nanoparticles, such as mesoporous silica nanoparticles 
and polymeric materials has been winning the race for effective cancer management. 
In example, mesoporous silica nanoparticles loaded with topotecan and externally 
modified with poly (acrylic acid) co-synthesized with chitosan, were investigated 
for their efficacy against triple-negative breast cancer (MDA-MB-231) and multi-
drug resistant MCF-7 cells. The external layer is conjugated also with quercetin as a 
second drug. Moreover, arginine-glycine-aspartic acid peptide was conjugated on 
the nanoparticles inducing their uptake from the cancer cells via integrin receptor-
mediated endocytosis. It was concluded that the system promoted molecular activa-
tion and cell death [31]. Folate modified liposomes loaded with bleomycin were 
prepared via film hydration and studied for their anticancer activity and apoptosis 
induction. According to the MTT assay, the nano-liposomal formulations showed 
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greater efficacy in human cervix carcinoma HeLa, and human breast carcinoma 
MCF-7 cells. Due to the modification of formulations with folic acid, an improved 
uptake by HeLa cells was confirmed. Additionally, the folate nano-liposomes with 
bleomycin effectively promoted apoptotic cell death as well as a cell-cycle arrest in 
HeLa cells especially at the G2/M phase [32]. Another system composed of modified 
chitosan nanoparticles and methotrexate was investigated as a potent anticancer 
system. Two molecules, L-cysteine and folic acid were conjugated to chitosan; the 
decorated nanoparticles when studied in a reducing environment similar to tumor 
cells, released the drug as desired. Moreover, the nanoparticles induced anticancer 
activity on HeLa cells in a dose and time-dependent manner while they demon-
strated selective cellular uptake [33]. Another research involved the incorporation 
of doxorubicin into folic acid-modified lactoglobulin nanoparticles and studied for 
their anticancer potential against MCF-7 and MDA-MB-231, BC and triple-negative 
BC cells. It was revealed an important inhibition of cell proliferation and promotion 
of apoptosis [34].
DR5 which belongs to the TNFR family has been proposed as a potential target 
for cancer. An interesting study investigated the application of poly(ethylene 
glycol) decorated poly(lactic-co-glycolic acid) nanoparticles as potent anticancer 
carriers. The nanoparticles were further conjugated with DR5-specific antibody 
conatumumab and impregnated with camptothecin. The stealth nanocarriers 
promoted pro-apoptotic effects of the platform in vivo using HCT116 adenocarci-
noma xenografts [35]. Another research evaluated the development of nanoparticles 
comprised from copolymers between poly(ε-caprolactone)-PCL and poly(ethylene 
glycol)-PEG as well as PEG, PCL, and poly(lactic acid)-PLA as potent carriers of 
auraptene. The triblock PCL-PEG-PCL and pentablock PLA-PCL-PEG-PCL-PLA 
copolymers were formulated on nanoparticles and examined for their characteris-
tics. According to the results, the PLA-PCL-PEG-PCL-PLA nanoparticles showed 
enhanced cellular uptake as well as cytotoxicity. In further, the nano-formulations 
incorporating auraptene promoted the apoptotic cell death on HT-29 colon cancer 
cells. The real-time PCR revealed as apoptosis marker the Bax /Bcl2 expression ratio 
which was increased in the case of pentablock nanoparticles [36]. Nanocarriers 
based on mPEGylated Dendron conjugated with glycylphenylalanylleucylglycine 
tetra-peptide spacer and doxorubicin were studied for their efficacy against mul-
tidrug resistance of cancer chemotherapy. The in vitro studies revealed that the 
nanoparticles can accumulate in the nuclei of MCF-7/ADR cells and they are poten-
tially cytotoxic leading to apoptosis. Moreover, the nanoparticles showed enhanced 
therapeutic efficiency against multidrug resistance xenograft tumors and thus they 
can be applied as potent anticancer carriers that can initiate the lysosomal apoptosis 
pathway [37]. Nano-formulations based on triphenylphosphine, Pluronic F127, and 
hyaluronic acid, formulated on nanomicelles able to incorporate paclitaxel, anti-
cancer drug. The nanosystem showed inhibition of A549/ADR cells. Moreover, the 
nanomicelles entered acidic lysosomes through macropinocytosis, and accumulate 
in the mitochondria over a day, in A549/ADR cells. The nanomicelles induced the 
permeabilization of the mitochondrial outer membrane via hindering anti-apoptotic 
Bcl-2, resulting in the release of cytochrome C as well as caspase-3 and caspase-9 
activation. Accordingly, when the nanoformulations studied in A549/ADR xenograft 
tumor model and a drug-resistant breast cancer mice model with lung metastasis, 
demonstrated promising cancer targeting and desirable anticancer efficiency [38]. 
A promising way to initiate cancer cell apoptosis is to targeted deliver cytochrome 
c, which can mediate apoptotic cell death if released from the mitochondria to the 
cytoplasm. Thus, an innovative nanosystem based on Cytochrome c was developed 
in order to promote the apoptotic death of cancer cells when is delivered. The nano-
carriers of cytochrome c were modified with poly (lactic-co-glycolic) acid-SH via the 
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linker succinimidyl 3-(2-pyridyldithio) propionate so as to prevent the degradation 
possibility. The nanoformulations when incubated with HeLa cells exhibited cyto-
toxicity and the promotion of apoptosis in HeLa cells was also demonstrated [39]. 
Carbon dots have been widely studied as anticancer systems, i.e. carbon dots devel-
oped via ultrasonication of sucrose were modified with Gemcitabine and studied for 
their activity on MCF-7 and HeLa cell lines. The cytocompatible nano-formulations 
expressed desirable bioactivity and cytotoxicity against the cell lines. Moreover, the 
nano-formulations did not affect the healthy cells in such extent as they acted against 
cancerous cells. The most important outcome of the study is that the Gemcitabine 
conjugated carbon dots promoted early and late apoptotic cell deaths in the MCF-7 
and HeLa cancer cell lines [40]. Graphene oxide modified with GE11 peptide was 
fabricated in order to efficiently targeted deliver oridonin on cancerous cells. The 
modified graphene oxide showed improved cellular uptake in KYSE-30 and EC109 
esophageal cells compared to healthy cells. The oridonin loaded carriers were able to 
accumulate into lysosomes while they desirably hinder the viability of cancer cells. In 
addition, the developed system promoted apoptosis of the aforementioned cancer-
ous cell lines [41]. Figure 1 summarizes the possible mechanisms involving when 
nanocarriers are delivered to cells and induce apoptosis.
Several active compounds can be used for therapeutic purposes but miRNAs 
may also be employed for this purpose. The second part focuses on miRNAs as 
anticancer agents.
3. APOPTOTIC MicroRNAs (miRNA)
3.1 How miRNAs work to silence genes
To generate mature miRNAs, sequential steps are followed. First, RNA 
Polymerase II transcribes primary miRNAs (abbreviated as pri-miRNA). These 
Figure 1. 
A summary of multifunctional nanocarriers inducing apoptosis.
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molecules can be translated from both intergenic and intragenic regions [42]. Then 
in order to generate pre-miRNAs with hairpin precursors, pri-miRNAs are processed 
by Drosha, an RNase III enzyme and by Pasha, a dsRNA-binding protein [43]. After 
this step, pre-miRNAs get escorted out of the nucleus with the help of exportin 5 
[44]. And the pre-miRNA gets further processed in cytoplasm by Dicer enzyme 
which is an RNase III endonuclease, this enzyme works to remove the hairpin loop 
and make a double stranded duplex miRNA [44]. Then this double stranded struc-
ture retains the active strand while passenger stand gets degraded. The active strand 
interacts with RNA-induced silencing complex (abbreviated as RISC) in order to 
function. RISC is a complex formed by multiple proteins with its key proteins being 
argonaute 2 (abbreviated as Ago2) and transactivation-responsive RNA-binding 
protein (abbreviated as TRBP), and it includes miRNA or siRNA in order to use 
them as a template [45]. With these RNA templates the complex is able to recognize 
their complementary mRNA. The characteristic features of the target gene for 
an effective binding can be; seed region, a target sequence that is conserved, 3′ 
untranslated region of miRNA available for binding but recent studies show the 
binding of a target may also happen in 5′ untranslated region, promoter regions or 
open reading frames [45]. The pairing of the miRNA template and its target mRNA 
differs between plant cells and animal cells. In the plant cells, the pairing is fully 
complementary between miRNA and mRNA. But in animal cells, this pairing is 
not fully complementary there are base mismatches even though this base pairing 
follows a pattern. But there is a small sequence with 2–8 nucleotides of length which 
is a perfect base pairing that is called seed region [46]. This region is a conserved 
heptametrical sequence that is always perfectly matched and it is mostly found 
towards the 5′ end of miRNA [47]. With the binding of mRNA and miRNA, down-
regulation is tried to be achieved and this can be achieved via enzymatic cleavage of 
the mRNA leading to its further destruction by the cell or blocking the translation 
by preventing ribosome subunit from binding to mRNA [48]. And the matching 
degree of target and miRNA plays a role in the decision of which mechanism will 
happen for downregulation to occur, if the target is fully complementary then cleav-
age of mRNA will happen but if it is not fully complementary stability alteration or 
repression of translation may occur [43].
3.2 miRNAs in apoptosis
miRNAs are known to have a regulatory effect on apoptosis via their regula-
tion on both pro-apoptotic and anti-apoptotic genes. So, miRNAs can work to be 
both inhibitory and stimulatory depending on the miRNA and the cell context. 
Also, alteration of the expression of regulatory genes in the apoptotic process by 
miRNAs is not limited to one of the extrinsic and intrinsic pathways. And the effect 
of miRNAs can both be direct and indirect. For example, miR-21 is a miRNA that 
directly affects its target, inhibiting FasL in order to increase apoptosis but miR-
130a is a miRNA that affects TRAIL resistance in order to effect other miRNAs that 
will eventually cause a change in apoptotic process [49].
For their indirect effects, miRNAs can be seen to function in both feedback 
and feedforward loops. Feedback loop effects can change depending on the cell 
context, miRNA and transcription factors as the regulators may have the same or 
opposite effects [50]. And, in feed-forward loops, transcription factors can be seen 
to regulate both the target gene and miRNA, which also regulates the transcription 
factor [50]. To regulate genes, miRNAs work together with transcription factors 
in a highly coordinated manner. Since they can show their effects on mRNAs after 
the transcription of said mRNA, they usually locate downstream to transcription 
factors [51].
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In the intrinsic pathway, p53 and BCL-2 families play an important role. 
MiRNAs can alter their expression to regulate the intrinsic pathway. As miRNAs 
regulate the levels of p53, this tumor suppressor actually has an effect on the 
miRNAs as well by functioning to regulate miRNA expression and maturation 
[52]. For an example of p53 regulating miRNAs and how its mutation can cause a 
change, we can look at miR-16 and miR-143. Their processing is dependent on the 
interaction between p53 and Drosha complex so if there is a mutation in the DNA 
binding domain of p53, their processing cannot be achieved and cell proliferation 
will be suppressed [45]. Activation of p53 is found to be increasing the expression 
of 30 or more miRNAs including miRNAs like let7a, miR-34a and miR-15a/16 
which are tumor suppressors [53]. BCL-2 is an anti-apoptotic protein that is 
generally overexpressed in tumors. Three pro-apoptotic miRNAs, miR-24, miR-195 
and miR-365, work to down-regulate BCL2 expression via their binding to BCL-2 
gene’s 3′ untranslated region [53]. With this interaction, pro-apoptotic miRNAs 
lead to apoptosis. Extrinsic pathway is also regulated by miRNAs. Some miRNAs 
were found to regulate TRAIL-induced apoptosis directly and indirectly [43]. 
miR-221 and miR-222 can be an example of this regulation since they are found 
to have altering expressions between TRAIL resistant and sensitive cells, resistant 
cells being the ones with up-regulation of these miRNAs [43]. Another example 
can be miR-200c since it directly targets FAP-1, a phosphatase that works to inhibit 
apoptosis [43].
An example to miRNAs with effects not limited to one site is miR-21. We can 
observe its effects on both non-small cell lung carcinoma (NSCLC) and dif-
fuse large B-cell lymphoma (DLBCL). In NSCL, miR-21 effects apoptosis via its 
inhibition on PI3K/Akt/NF-kB pathway and also it is found that miR-21 targets 
apoptosis-stimulating protein of p53 (ASPP2) which is a protein that functions in 
tumorigenesis [54]. And it was found that in early-stage samples of NSCL cells, 
miR-21 expression was increased when compared to the control [55]. The experi-
ments revealed that in NSCL cells, miR-21 down-regulation led to the repression of 
EMT signaling pathway, cell migration and invasion, and miR-21 inhibition led to 
triggering of apoptosis [54]. Both in vitro and in vivo, miR-21 inhibited PI3K/Akt/
NF-κB signaling pathway and promoted caspase-dependent pathway of apoptosis. 
MiR-21 also is known to have high expression levels in B-cell lymphoma. In DLBCL, 
its effect on apoptosis can be seen via regulation of phosphatase and tensin homolog 
(PTEN). The expression level of miR-21 in patient samples was found to be more 
than the healthy samples, and these levels were also negatively correlated with 
expression level of PTEN [14]. Other miRNAs that have an effect on PTEN are 
miR-130 family. This family of miRNAs which corresponds to miR-130b, miR-301a 
and miR-301b, are found to have high expression levels in bladder cancer samples 
compared to normal ones. Via their regulation upon PTEN they also regulate focal 
adhesion kinase (FAK) and Akt phosphorylation, and lead to cell migration and 
invasion increase in bladder cancer. Experiments showed that the inhibition of this 
family causes down-regulation of FAK and Akt phosphorylation and this effects cell 
migration and invasion negatively, so it can be said that they have an important role 
in the progression of bladder cancer [56].
As it can be seen from the examples, the effects of miRNAs are diversifiable 
depending on the gene they are affecting or their expression level. The alteration 
of their expression leads to interchangeable role of miRNAs as oncogenes or tumor 
suppressors. Generally, the miRNAs that are down-regulated in the cancer tissues 
are considered to be tumor suppressors, as pro-apoptotic miRNAs they work for 
apoptosis to happen. miR-7, miR335 and miR-608 are examples of this type of 
miRNAs since they target BCL-2 family, and miR-203 and miR-143 can be other 
examples as they target PKC family [57]. On the other hand, other miRNA examples 
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can be seen as upregulated in the cancer tissues, as antiapoptotic miRNAs they 
induce apoptosis to allow uncontrollable proliferation. miR-197, miR-21 and miR-
212 can be the examples of these kind of miRNAs [57].
Our current research based on developing target specific drug candidates 
over breast cancer cell lines. The array studies indicated that non-coding RNA 
hsa-miR-215 greatly enhance the inhibitor compound efficiency on MCF-7 and 
MDA-MB-231 breast cancer cell lines. The expression of hsa-miR-215 decreases in 
breast cancer cell lines compared to non-cancerous breast MCF10-A cell line. Over 
expressing this miRNA by transfecting into the cancerous cell lines drive the cells to 
apoptosis. Therefore, synergetic effect of the inhibitor compound along with hsa-
miR-215 mimic augment anticancer treatment. A nanocarrier is being developed 
with hsa-miR-215 and inhibitor compound (patent pending). This formulation is 
designed for apoptosis-based therapeutic approach for breast cancer treatment. 
The utilization of carrier system along with miRNAs and inhibitor compounds 
introduced in this study for therapeutic purposes has the potential of clinical 
applications.
4. Future perspectives
Regulated cell death can be employed in cancer treatment since the apoptotic 
process can restrain survival of abnormal cells. miRNAs regulate distinct pathways 
and target the pathway’s components. Cancer cells metabolic rate is higher and 
block apoptosis for survival strategy. Factors driving cancer cells to apoptosis can 
be used for treatment purposes. Recent advances in drug discovery and miRNA 
handling help these designs. Inhibitor compounds and miRNA-based therapeutics 
in oncology are promising and although face some challenges.
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